Neurodegeneration and Neuroprotection in Parkinson Disease

被引:138
作者
Fahn S. [1 ]
Sulzer D. [1 ]
机构
[1] Department of Neurology, Columbia University, New York
来源
NeuroRX | 2004年 / 1卷 / 1期
关键词
alpha-synuclein; PARK genes; Parkin gene; ubiquitin pathway;
D O I
10.1602/neurorx.1.1.139
中图分类号
学科分类号
摘要
Many of the motoric features that define Parkinson disease (PD) result primarily from the loss of the neuromelanin (NM)-containing dopamine (DA) neurons of the substantia nigra (SN), and to a lesser extent, other mostly catecholaminergic neurons, and are associated with cytoplasmic "Lewy body" inclusions in some of the surviving neurons. While there are uncommon instances of familial PD, and rare instances of known genetic causes, the etiology of the vast majority of PD cases remains unknown (i.e., idiopathic). Here we outline genetic and environmental findings related to PD epidemiology, suggestions that aberrant protein degradation may play a role in disease pathogenesis, and pathogenetic mechanisms including oxidative stress due to DA oxidation that could underlie the selectivity of neurodegeneration. We then outline potential approaches to neuroprotection for PD that are derived from current notions on disease pathogenesis. © 2004 The American Society for Experimental NeuroTherapeutics, Inc.
引用
收藏
页码:139 / 154
页数:15
相关论文
共 158 条
[1]  
Fahn S., Przedborski S., Parkinsonism, Merritt's neurology, pp. 679-693, (2000)
[2]  
Fahn S., Description of Parkinson's disease as a clinical syndrome, Ann NY Acad Sci, 991, pp. 1-14, (2003)
[3]  
Seibyl J., Marek K., Quinlan D., Sheff K., Zoghbi S., Zea-Ponce Y., Et al., Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease, Ann Neurol, 38, pp. 589-598, (1995)
[4]  
Eidelberg D., Moeller J., Ishikawa T., Dhawan V., Spetsieris P., Chaly T., Et al., Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET, J Nucl Med, 36, pp. 378-383, (1995)
[5]  
Snow B., Lee C., Schulzer M., Mak E., Calne D., Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinsonism, Ann Neurol, 36, pp. 759-764, (1994)
[6]  
Morrish P., Sawle G., Brooks D., An [F-18]dopa-PET and clinical study of the rate of progression in Parkinson's disease, Brain, 119, pp. 585-591, (1996)
[7]  
Benamer H., Patterson J., Wyper D., Hadley D., Macphee G., Grosset D., Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake, Mov Disord, 15, pp. 692-698, (2000)
[8]  
Mayeux R., Marder K., Cote L., Denaro J., Hemenegildo N., Mejia H., Et al., The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993, Am J Epidemiol, 142, pp. 820-827, (1995)
[9]  
de Rijk M., Tzourio C., Breteler M., Dartigues J., Amaducci L., Lopez-Pousa S., Et al., Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease, J Neurol Neurosurg Psychiatry, 62, pp. 10-15, (1997)
[10]  
Bower J., Maraganore D., McDonnell S., Rocca W., Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease, Mov Disord, 15, pp. 819-825, (2000)